Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5026447 | 1.00 | KMT2A (0.42) | KMT2ALMNAGAAHDAC3HDAC11 | |
| SCHEMBL4939718 | 1.00 | KMT2A (0.42) | KMT2ALMNAGAAHDAC3HDAC11 | |
| SCHEMBL6818436 | 0.95 | KMT2A (0.41) | KMT2ALMNAGAAHDAC3HDAC11 | |
| SCHEMBL3954018 | 0.95 | KMT2A (0.41) | KMT2ALMNAGAAHDAC3HDAC11 | |
| SCHEMBL6810038 | 0.95 | KMT2A (0.41) | KMT2ALMNAGAAHDAC3HDAC11 | |
| SCHEMBL475421 | 0.89 | LMNA (0.48) | KMT2ALMNAGAAPOLBCNR1 | |
| SCHEMBL78947 | 0.89 | LMNA (0.48) | KMT2ALMNAGAAPOLBCNR1 | |
| SCHEMBL317779 | 0.89 | LMNA (0.48) | KMT2ALMNAGAAPOLBCNR1 | |
| SCHEMBL24537183 | 0.84 | HDAC3 (0.38) | KMT2ALMNAGAAHDAC3HDAC11 | |
| Methylene Chloride SCHEMBL28127317 | 0.82 | LMNA (0.47) | KMT2ALMNAGAAPOLBCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3455224-B1 | SUBSTITUTED 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRIDINE-3(2H)-ONES AND 2,5,6,7-TETRAHYDRO-3H-PYRROLO[2,1-C][1,2,4]TRIAZOL-3-ONES, AND USE THEREOF | BAYER AG (DE) | 2024-03-27 | — | — | EP | disclosed |
| US-20110237511-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | MERCK FROSST CANADA (CA) | 2011-09-29 | — | — | US | disclosed |
| US-20110237511-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | MERCK FROSST CANADA (CA) | 2011-09-29 | — | — | US | disclosed |
| US-RE42562-E1 | EP4 receptor agonist, compositions and methods thereof | MERCK FROSST CANADA (CA) | 2011-07-19 | — | — | US | disclosed |
| US-RE42562-E1 | EP4 receptor agonist, compositions and methods thereof | MERCK FROSST CANADA (CA) | 2011-07-19 | — | — | US | disclosed |
| US-20080058375-A1 | Bone disorders; osteoporosis; antihistamines; sexual disorders; antiinflammatory agents; antiarthritic agents; vision defects; antiulcer agents | ELWORTHY TODD R | 2008-03-06 | — | — | US | disclosed |
| US-20080058375-A1 | Bone disorders; osteoporosis; antihistamines; sexual disorders; antiinflammatory agents; antiarthritic agents; vision defects; antiulcer agents | ELWORTHY TODD R | 2008-03-06 | — | — | US | disclosed |
| US-20080058375-A1 | Bone disorders; osteoporosis; antihistamines; sexual disorders; antiinflammatory agents; antiarthritic agents; vision defects; antiulcer agents | ELWORTHY TODD R | 2008-03-06 | — | — | US | disclosed |
| US-7271183-B2 | 2-Piperidone derivatives as prostaglandin agonists | ROCHE PALO ALTO LLC (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271183-B2 | 2-Piperidone derivatives as prostaglandin agonists | ROCHE PALO ALTO LLC (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271183-B2 | 2-Piperidone derivatives as prostaglandin agonists | ROCHE PALO ALTO LLC (US) | 2007-09-18 | — | — | US | disclosed |
| US-7238710-B2 | EP4 receptor agonist, compositions and methods thereof | MERCK FROSST CANADA, LTD. (CA) | 2007-07-03 | — | — | US | disclosed |
| US-7238710-B2 | EP4 receptor agonist, compositions and methods thereof | MERCK FROSST CANADA, LTD. (CA) | 2007-07-03 | — | — | US | disclosed |
| CN-1735597-A | 2-piperidone derivatives as prostaglandin agonists | HOFFMANN LA ROCHE (CH) | 2006-02-15 | — | — | CN | disclosed |
| EP-1585729-A1 | 2-PIPERIDONE DERIVATIVES AS PROSTAGLANDIN AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004063158-A1 | 2-PIPERIDONE DERIVATIVES AS PROSTAGLANDIN AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-07-29 | — | — | WO | disclosed |
| US-20040142969-A1 | 2-Piperidone derivatives as prostaglandin agonists | ROCHE PALO ALTO LLC | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058375-A1 | Bone disorders; osteoporosis; antihistamines; sexual disorders; antiinflammatory agents; antiarthritic agents; vision defects; antiulcer agents | C3AR1, C1R, HRH4 | KMT2A 2482/4885LMNA 1428/4885GAA 1279/4885 |
| US-20040142969-A1 | 2-Piperidone derivatives as prostaglandin agonists | PTGER1, PTGER2, PTGER4 | KMT2A 3116/4885LMNA 1940/4885GAA 4538/4885 |
| US-20110237511-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | PTGER4, PTGER1, PTGER3 | KMT2A 2893/4885LMNA 2765/4885GAA 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.